Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2020

Open Access 01-12-2020 | Breast Surgery | Commentary

Breast cancer surgery during the Covid-19 pandemic: a monocentre experience from the Regina Elena National Cancer Institute of Rome

Authors: Fabio Pelle, Sonia Cappelli, Franco Graziano, Loredana Piarulli, Flavia Cavicchi, Domenico Magagnano, Assunta De Luca, Roy De Vita, Marcello Pozzi, Maurizio Costantini, Antonio Varanese, Massimo Panimolle, Pietro Paolo Gullo, Maddalena Barba, Patrizia Vici, Enrico Vizza, Francesco Cognetti, Giuseppe Sanguineti, Elena Saracca, Gennaro Ciliberto, Claudio Botti

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2020

Login to get access

Abstract

The Covid-19 pandemic has challenged hard the national health systems worldwide. According to the national policy issued in March 2020 in response to the evolving Covid-19 pandemic, several hospitals were re-configured as Covid-19 centers and elective surgery procedures were rescheduled according to the most recent recommendations. In addition, Covid-19 protected cancer hubs were established, including the Regina Elena National Cancer Institute of Rome, Central Italy. At our Institute, the Breast Surgery Department continued working under the sign of a multidisciplinary approach. The number of professional figures involved in case evaluation was reduced to a minimum and interactions took place in the full respect of the required safety measures. Treatments for benign disease, pure prophylactic surgery and elective reconstructive procedures were all postponed and priority was assigned to the histologically-proven malignant breast tumors and highly suspicious lesions. From March 15th though April 30th 2020, we treated a total of 79 patients. This number is fully consistent with the average quantitative standards reached by our Department under ordinary circumstances. Patients were mostly discharged the day after surgery and none was readmitted due to surgery-related late complications. More generally, post-operative complications rates were unexpectedly low, particularly in light of the relatively high number of reconstructive procedures performed in this emergency situation. A strict follow up was performed based on the close contact with the surgical staff by telephone, messaging apps and telemedicine.
Patients ascertainment for their Covid-19 status prior to hospital admission and hospital discharge allowed to maintain the “no-Covid-19” status at our Institution. In addition, during the aforementioned time window, none of the care providers developed SARS-CoV-2 infection or disease, as shown by the results of anti-SARS-CoV-2 immunoglobulin M and G profiling. In conclusions, elective breast cancer surgery procedures were successfully performed in a lockdown situation due to a novel viral pandemic. The well-coordinated regional and hospital efforts in terms of medical resource re-allocation and definition of clinical priorities allowed to maintain high quality standards of breast cancer care while ensuring safety to the cancer patients and care providers involved.
Literature
1.
go back to reference Onder G, Rezza G, Brusaferro S. JAMA. 2020; doi: 10.1001/jama.2020.4683. Onder G, Rezza G, Brusaferro S. JAMA. 2020; doi: 10.1001/jama.2020.4683.
3.
go back to reference WHO – Director-General’s opening remarks at the media briefing on COVID-19 – 11 March. (2020). http://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020. Accessed 05 May 2020. WHO – Director-General’s opening remarks at the media briefing on COVID-19 – 11 March. (2020). http://​www.​who.​int/​dg/​speeches/​detail/​who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.​ Accessed 05 May 2020.
4.
go back to reference van de Haar J, et al. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020; doi: 10.038/s41591-020-0874-8. van de Haar J, et al. Caring for patients with cancer in the COVID-19 era. Nat Med. 2020; doi: 10.038/s41591-020-0874-8.
5.
go back to reference Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Comment. Lancet Oncol. 2020;21(3):335–7.CrossRef Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Comment. Lancet Oncol. 2020;21(3):335–7.CrossRef
6.
go back to reference Yang X, Rui J, Jing Z, Wen L. Risk of COVID-19 for cancer patients. Comment. Lancet Oncol. 2020;21(3):335–7.CrossRef Yang X, Rui J, Jing Z, Wen L. Risk of COVID-19 for cancer patients. Comment. Lancet Oncol. 2020;21(3):335–7.CrossRef
9.
go back to reference De Vita R, Buccheri EM, Villanucci A, Pozzi M. Breast reconstruction actualized in nipple-sparing mastectomy and direct-to-implant, Prepectoral Polyurethane Positioning: Early Experience and Preliminary Results. Clin Cancer Breast. 2019;19(2):e358–63.CrossRef De Vita R, Buccheri EM, Villanucci A, Pozzi M. Breast reconstruction actualized in nipple-sparing mastectomy and direct-to-implant, Prepectoral Polyurethane Positioning: Early Experience and Preliminary Results. Clin Cancer Breast. 2019;19(2):e358–63.CrossRef
10.
go back to reference Fregatti P, Gipponi M, Giacchino M, Sparavigna M, Murelli F, Toni ML, et al. Breast Cancer Surgery During the Covid-19 Pandemic: An Observational Clinical Study of the Breast Surgery Clinic at Ospedale Policlinico San Martino – Genoa, Italy. In Vivo. 2020. https://doi.org/10.21873/invivo.11959. Fregatti P, Gipponi M, Giacchino M, Sparavigna M, Murelli F, Toni ML, et al. Breast Cancer Surgery During the Covid-19 Pandemic: An Observational Clinical Study of the Breast Surgery Clinic at Ospedale Policlinico San Martino – Genoa, Italy. In Vivo. 2020. https://​doi.​org/​10.​21873/​invivo.​11959.
Metadata
Title
Breast cancer surgery during the Covid-19 pandemic: a monocentre experience from the Regina Elena National Cancer Institute of Rome
Authors
Fabio Pelle
Sonia Cappelli
Franco Graziano
Loredana Piarulli
Flavia Cavicchi
Domenico Magagnano
Assunta De Luca
Roy De Vita
Marcello Pozzi
Maurizio Costantini
Antonio Varanese
Massimo Panimolle
Pietro Paolo Gullo
Maddalena Barba
Patrizia Vici
Enrico Vizza
Francesco Cognetti
Giuseppe Sanguineti
Elena Saracca
Gennaro Ciliberto
Claudio Botti
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2020
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-020-01683-y

Other articles of this Issue 1/2020

Journal of Experimental & Clinical Cancer Research 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine